Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non-small cell lung cancer.

ABSTRACT:

Purpose

Protein tyrosine phosphatase receptor type T (PTPRT), which is a well-known phosphatase and mutates frequently in melanoma and non-small cell lung cancer (NSCLC). Our research aims to elucidate its mutation association with immune checkpoint inhibitors (ICI) efficacy.

Methods

We integrated whole-exome sequencing (WES)-based somatic mutation profiles and clinical characteristics of 631 melanoma samples received ICI agents from eight studies and 109 NSCLC samples from two studies. For validation, 321 melanoma and 350 NSCLC immunotherapy samples with targeted next-generation sequencing (NGS) were employed. Besides, an independent NSCLC cohort contained 240 samples was also collected for further corroboration. Distinct immune infiltration was evaluated according to the P

SUBMITTER: Zhang W 

PROVIDER: S-EPMC8817076 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature